from Breakingviews:

Mylan injects adrenaline into healthcare debate

August 25, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Pfizer bets $14 bln it knows better than market

August 22, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Bristol-Myers suffers $21 bln self-inflicted wound

August 5, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Valeant may strain to engineer way out the in door

June 6, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

J&J’s corpulence defense weighs heavy

June 2, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Bayer’s Monsanto bid yields poor financial harvest

May 27, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Medical firms’ $18 bln merger lacks clear logic

May 3, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Abbott’s $25 bln buy inspires little investor hope

April 28, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Valeant plays chicken with death spiral

March 15, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Valeant CEO back with less power and no glory

February 29, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.